News

Filter

Current filters:

Mergers & Acquisitions

826 to 835 of 97252 results

BTG settles CroFab patent litigation with Bioclon and RDT

10-10-2014

UK specialist health care company BTG says it has settled its US patent infringement complaint against…

BTGCrofabInstituto BioclonLegalPatentsPharmaceuticalRare Disease TherapeuticsRare diseasesUSA

New Zealand approval of Novartis multiproduct proposal

10-10-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

NeurologicalNew ZealandOncologyPharmaceuticalRegulationRespiratory and Pulmonary

IQWiG finds added benefit of Novartis’ Gilenya not proven

IQWiG finds added benefit of Novartis’ Gilenya not proven

10-10-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

GermanyGilenyaNeurologicalNovartisPharmaceuticalPricingRegulation

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Biogen Idec files for Elocta approval in Europe

Biogen Idec files for Elocta approval in Europe

10-10-2014

US biotech firm Biogen Idec has submitted a Marketing Authorization Application (MAA) for Elocta (rFVIIIFc;…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

10-10-2014

Swiss drug major Novartis has reported data from a Phase III trial showing consistent efficacy in clearing…

DermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Biotron Phase II trial of BIT225 shows undetectable levels of hepatitis C 12 weeks after finishing treatment

Biotron Phase II trial of BIT225 shows undetectable levels of hepatitis C 12 weeks after finishing treatment

10-10-2014

All hepatitis C genotype 3 patients in a Phase II trial of BIT225, developed by Australian drug developer…

AustraliaBiotechnologyBiotronBIT225Nephrology and HepatologyResearch

826 to 835 of 97252 results

Back to top